Abbott Laboratories (ABT) DIvidends Date & History

Key Takeaways

• Quarterly dividend: Abbott Laboratories pays $0.63 per share each quarter, an annualized payout of roughly $2.52 per share.
• Dividend yield: The stock's yield sits around 2.4% to 2.5%, reflecting its steady share-price appreciation rather than an aggressive payout.
• Dividend growth streak: Abbott has raised its dividend for 54 consecutive years, placing it among the market's longest-running dividend growers.
• Payout ratio: The company distributes about 68% of trailing earnings and around 36% of cash flow as dividends, leaving meaningful room for reinvestment.
• Growth trajectory: Dividends have grown at a mid-to-high single-digit annual rate over the past several years, a hallmark of a dividend growth stock.

Dividend Overview

Abbott Laboratories (ABT) is a diversified healthcare company with established franchises in medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. Its dividend policy reflects a deliberate balance between rewarding shareholders and reinvesting in growth. The company pays a quarterly dividend of $0.63 per share, resulting in an annualized dividend of approximately $2.52 per share and a current yield of roughly 2.4% to 2.5%.

Abbott is best characterized as a dividend growth stock rather than a high-yield stock. While its yield is modest relative to traditional income names, its track record of consistent, inflation-beating increases makes it appealing to long-term investors. Payments follow a predictable quarterly schedule, with recent ex-dividend and payment dates occurring in January, April, July, and October of each year.

Dividend History and Growth

Abbott's dividend history is one of the strongest in the healthcare sector. The company has increased its dividend for 54 consecutive years, a distinction that places it among the elite "Dividend Kings" — companies with half a century or more of uninterrupted payout growth. That streak spans decades of business transformation, including the 2013 spinoff of its research-based pharmaceuticals business into AbbVie.

Growth has been steady rather than spectacular. The dividend has compounded at roughly a 9% to 10% annual rate over the past five years and about 10% over the past decade. Recent increases reflect this pattern: the quarterly payout rose from $0.55 in 2024 to $0.59 in 2025, and then to $0.63 in early 2026. This consistency underscores management's commitment to treating the dividend as a reliable, gradually rising return of capital to shareholders.

Dividend Sustainability and Payout Ratio

Abbott's dividend appears well-supported by its underlying cash generation. Based on trailing twelve-month earnings, the payout ratio is approximately 68% — a level that is higher than Abbott's historical average but still manageable for a mature healthcare franchise. Crucially, the dividend consumes only about 36% of free cash flow, indicating that earnings-based figures may understate the true flexibility of the balance sheet.

Abbott's diversified revenue base across medical devices, diagnostics, nutrition, and pharmaceuticals provides resilience against cyclical downturns in any single product category. The company maintains a solid investment-grade balance sheet, which further supports its ability to fund both the dividend and ongoing research and development. While the earnings-based payout ratio has risen in recent periods, the cash-flow coverage suggests the dividend remains comfortably within reach for management.

Dividend Compared to Industry Peers

Within the healthcare and medical-device landscape, Abbott's dividend profile sits in the middle of the pack on yield but near the top on consistency. Its yield of roughly 2.4% to 2.5% is modestly below that of diversified healthcare peers such as Johnson & Johnson and Medtronic (MDT), which often yield closer to 3% or more. By contrast, Abbott's yield is higher than many faster-growing device makers that pay little or no dividend.

Where Abbott distinguishes itself is durability. Few direct competitors can match a 54-year growth streak, which reflects both financial discipline and the stability of its cash flows. For investors weighing yield versus reliability, Abbott offers a lower starting income than some peers but with an unusually long record of uninterrupted growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. For investors researching dividend-paying healthcare names like Abbott, the AI Screener can help surface comparable opportunities and refine a watchlist with precision.

Is This Stock Attractive for Dividend Investors?

Abbott Laboratories (ABT) is likely to resonate most with dividend growth investors and long-term, buy-and-hold investors rather than those seeking maximum current income. Its yield in the mid-2% range is modest, so investors primarily focused on generating high immediate cash flow may find higher-yielding alternatives elsewhere in healthcare. However, for investors who prioritize a rising income stream over time, Abbott's 54-year growth streak and mid-to-high single-digit annual dividend growth are compelling characteristics.

The stock may also appeal to conservative, total-return-oriented investors who value a diversified healthcare business with recurring revenue and a strong balance sheet. The dividend's healthy free-cash-flow coverage suggests the payout is unlikely to be a source of stress even during earnings volatility. Ultimately, Abbott fits the profile of a foundational, compounding position for investors willing to accept a lower starting yield in exchange for a long, dependable record of dividend growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations